STOCK TITAN

[144] Palantir Technologies Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Hoth Therapeutics, Inc. (NASDAQ: HOTH) filed a Form S-8 to register 2,000,000 additional common shares for issuance under its Amended & Restated 2022 Omnibus Equity Incentive Plan. Following shareholder approval on 5-Aug-2025, the total pool available under the plan rose to 3,091,317 shares, up from 1,091,317. The filing is made pursuant to General Instruction E, incorporating prior S-8 registrations (File Nos. 333-265984, 333-274125, 333-281610).

The company is classified as a non-accelerated filer and smaller reporting company. No financial results, earnings guidance, or transactional disclosures are included; the document solely registers equity compensation securities. Sheppard, Mullin, Richter & Hampton LLP provided the legal opinion (Exhibit 5.1) and WithumSmith+Brown, PC consented as auditor (Exhibit 23.1).

Once effective, the newly registered shares can be issued through option, RSU or other award agreements listed in the exhibit index. Signature pages include CEO Robb Knie and CFO David Briones, with a blanket power of attorney for future amendments.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) ha depositato un modulo Form S-8 per registrare 2.000.000 di azioni ordinarie aggiuntive da emettere nell'ambito del suo Piano di Incentivi Azionari Omnibus Modificato e Ristabilito 2022. Dopo l'approvazione degli azionisti il 5 agosto 2025, il totale delle azioni disponibili nel piano è salito a 3.091.317 azioni, rispetto a 1.091.317 precedenti. Il deposito è effettuato in conformità con l'Istruzione Generale E, incorporando registrazioni S-8 precedenti (File Nos. 333-265984, 333-274125, 333-281610).

L'azienda è classificata come non-accelerated filer e smaller reporting company. Non sono inclusi risultati finanziari, previsioni sugli utili o comunicazioni transazionali; il documento registra esclusivamente titoli per compensi azionari. Sheppard, Mullin, Richter & Hampton LLP ha fornito l'opinione legale (Esibizione 5.1) e WithumSmith+Brown, PC ha fornito il consenso come revisore (Esibizione 23.1).

Una volta efficace, le azioni appena registrate possono essere emesse tramite opzioni, RSU o altri accordi di premio elencati nell'indice delle esibizioni. Le pagine delle firme includono il CEO Robb Knie e il CFO David Briones, con una procura generale per future modifiche.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) presentó un Formulario S-8 para registrar 2.000.000 acciones comunes adicionales para su emisión bajo su Plan de Incentivos de Capital Omnibus Modificado y Restablecido 2022. Tras la aprobación de los accionistas el 5 de agosto de 2025, el total disponible bajo el plan aumentó a 3.091.317 acciones, desde 1.091.317. La presentación se realiza conforme a la Instrucción General E, incorporando registros S-8 previos (Números de Archivo 333-265984, 333-274125, 333-281610).

La compañía está clasificada como non-accelerated filer y smaller reporting company. No se incluyen resultados financieros, pronósticos de ganancias ni divulgaciones transaccionales; el documento registra únicamente valores de compensación accionaria. Sheppard, Mullin, Richter & Hampton LLP proporcionó la opinión legal (Exhibición 5.1) y WithumSmith+Brown, PC dio su consentimiento como auditor (Exhibición 23.1).

Una vez efectivo, las acciones registradas podrán emitirse mediante opciones, RSU u otros acuerdos de premio listados en el índice de exhibiciones. Las páginas de firma incluyen al CEO Robb Knie y al CFO David Briones, con un poder notarial general para futuras enmiendas.

Hoth Therapeutics, Inc. (NASDAQ: HOTH)는 수정 및 재작성된 2022년 종합 주식 인센티브 계획에 따라 추가로 2,000,000주 보통주를 등록하기 위해 Form S-8을 제출했습니다. 2025년 8월 5일 주주 승인 이후, 계획 하에서 사용 가능한 총 주식 수는 1,091,317주에서 3,091,317주로 증가했습니다. 이 제출은 일반 지침 E에 따라 이전 S-8 등록(파일 번호 333-265984, 333-274125, 333-281610)을 포함하여 이루어졌습니다.

회사는 비가속 신고자(non-accelerated filer)소형 보고 회사(smaller reporting company)로 분류됩니다. 재무 결과, 수익 전망 또는 거래 공개는 포함되어 있지 않으며, 문서는 주식 보상 증권 등록만을 위한 것입니다. Sheppard, Mullin, Richter & Hampton LLP가 법률 의견서(증거 5.1)를 제공했으며 WithumSmith+Brown, PC가 감사인 동의서(증거 23.1)를 제출했습니다.

효력이 발생하면 새로 등록된 주식은 옵션, RSU 또는 전시 색인에 나열된 기타 상여 계약을 통해 발행될 수 있습니다. 서명 페이지에는 CEO Robb Knie와 CFO David Briones가 포함되어 있으며, 향후 수정에 대한 포괄 위임장이 포함되어 있습니다.

Hoth Therapeutics, Inc. (NASDAQ : HOTH) a déposé un formulaire S-8 pour enregistrer 2 000 000 d'actions ordinaires supplémentaires à émettre dans le cadre de son Plan d'Incitation Globale aux Actions 2022 modifié et révisé. Suite à l'approbation des actionnaires le 5 août 2025, le total disponible dans le plan est passé à 3 091 317 actions, contre 1 091 317 auparavant. Le dépôt est effectué conformément à l'Instruction Générale E, incorporant les enregistrements S-8 antérieurs (numéros de dossier 333-265984, 333-274125, 333-281610).

La société est classée comme non-accelerated filer et smaller reporting company. Aucun résultat financier, prévision de bénéfices ou divulgation transactionnelle n'est inclus ; le document se limite à l'enregistrement de titres de rémunération en actions. Sheppard, Mullin, Richter & Hampton LLP a fourni l'avis juridique (Exhibit 5.1) et WithumSmith+Brown, PC a donné son consentement en tant qu'auditeur (Exhibit 23.1).

Une fois effectif, les actions nouvellement enregistrées pourront être émises via des options, des RSU ou d'autres accords de récompense listés dans l'index des pièces. Les pages de signature comprennent le PDG Robb Knie et le directeur financier David Briones, avec une procuration générale pour les modifications futures.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) hat ein Formular S-8 eingereicht, um zusätzlich 2.000.000 Stammaktien zur Ausgabe im Rahmen seines geänderten und neu gefassten Omnibus-Aktienanreizplans 2022 zu registrieren. Nach der Zustimmung der Aktionäre am 5. August 2025 erhöhte sich der Gesamtpool unter dem Plan auf 3.091.317 Aktien, zuvor 1.091.317. Die Einreichung erfolgt gemäß Allgemeiner Anweisung E und beinhaltet frühere S-8-Registrierungen (Aktenzeichen 333-265984, 333-274125, 333-281610).

Das Unternehmen ist als non-accelerated filer und smaller reporting company klassifiziert. Es sind keine Finanzergebnisse, Gewinnprognosen oder transaktionsbezogenen Offenlegungen enthalten; das Dokument dient ausschließlich der Registrierung von Aktienvergütungswertpapieren. Sheppard, Mullin, Richter & Hampton LLP erteilte die Rechtsmeinung (Anlage 5.1) und WithumSmith+Brown, PC stimmte als Prüfer zu (Anlage 23.1).

Nach Wirksamwerden können die neu registrierten Aktien durch Optionen, RSUs oder andere im Ausstellungsverzeichnis aufgeführte Prämienvereinbarungen ausgegeben werden. Die Unterschriftsseiten enthalten CEO Robb Knie und CFO David Briones, mit einer umfassenden Vollmacht für künftige Änderungen.

Positive
  • Shareholder approval on 5-Aug-2025 demonstrates investor support for the equity incentive plan.
  • Expanded share reserve ensures the company can continue to grant stock-based awards to attract and retain talent.
Negative
  • Potential dilution: registration of 2,000,000 additional shares may increase the share count when awards are exercised or vest.

Insights

TL;DR: Registers 2 M new plan shares; routine, limited market impact.

The filing simply tops up the 2022 equity plan, bringing capacity to ~3.1 M shares. This is a standard administrative action that enables continued stock-based compensation. While the pool expansion could introduce incremental dilution when awards vest, no immediate issuance or financial outlay occurs. Because Hoth is a micro-cap with frequent equity incentives, the additional shares help attract talent but do not, by themselves, alter valuation fundamentals. No change to control provisions or plan terms beyond share count is disclosed.

TL;DR: Shareholders approved plan amendment; governance procedure appears proper.

The document confirms shareholder authorization for the increase, satisfying best-practice governance. Prior S-8 filings are cross-referenced, and requisite consents/opinions are attached. The power-of-attorney language is typical. No red flags around board approval, timing, or required disclosures emerge. Therefore, the action is procedurally sound and not materially impactful to governance risk profiles.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) ha depositato un modulo Form S-8 per registrare 2.000.000 di azioni ordinarie aggiuntive da emettere nell'ambito del suo Piano di Incentivi Azionari Omnibus Modificato e Ristabilito 2022. Dopo l'approvazione degli azionisti il 5 agosto 2025, il totale delle azioni disponibili nel piano è salito a 3.091.317 azioni, rispetto a 1.091.317 precedenti. Il deposito è effettuato in conformità con l'Istruzione Generale E, incorporando registrazioni S-8 precedenti (File Nos. 333-265984, 333-274125, 333-281610).

L'azienda è classificata come non-accelerated filer e smaller reporting company. Non sono inclusi risultati finanziari, previsioni sugli utili o comunicazioni transazionali; il documento registra esclusivamente titoli per compensi azionari. Sheppard, Mullin, Richter & Hampton LLP ha fornito l'opinione legale (Esibizione 5.1) e WithumSmith+Brown, PC ha fornito il consenso come revisore (Esibizione 23.1).

Una volta efficace, le azioni appena registrate possono essere emesse tramite opzioni, RSU o altri accordi di premio elencati nell'indice delle esibizioni. Le pagine delle firme includono il CEO Robb Knie e il CFO David Briones, con una procura generale per future modifiche.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) presentó un Formulario S-8 para registrar 2.000.000 acciones comunes adicionales para su emisión bajo su Plan de Incentivos de Capital Omnibus Modificado y Restablecido 2022. Tras la aprobación de los accionistas el 5 de agosto de 2025, el total disponible bajo el plan aumentó a 3.091.317 acciones, desde 1.091.317. La presentación se realiza conforme a la Instrucción General E, incorporando registros S-8 previos (Números de Archivo 333-265984, 333-274125, 333-281610).

La compañía está clasificada como non-accelerated filer y smaller reporting company. No se incluyen resultados financieros, pronósticos de ganancias ni divulgaciones transaccionales; el documento registra únicamente valores de compensación accionaria. Sheppard, Mullin, Richter & Hampton LLP proporcionó la opinión legal (Exhibición 5.1) y WithumSmith+Brown, PC dio su consentimiento como auditor (Exhibición 23.1).

Una vez efectivo, las acciones registradas podrán emitirse mediante opciones, RSU u otros acuerdos de premio listados en el índice de exhibiciones. Las páginas de firma incluyen al CEO Robb Knie y al CFO David Briones, con un poder notarial general para futuras enmiendas.

Hoth Therapeutics, Inc. (NASDAQ: HOTH)는 수정 및 재작성된 2022년 종합 주식 인센티브 계획에 따라 추가로 2,000,000주 보통주를 등록하기 위해 Form S-8을 제출했습니다. 2025년 8월 5일 주주 승인 이후, 계획 하에서 사용 가능한 총 주식 수는 1,091,317주에서 3,091,317주로 증가했습니다. 이 제출은 일반 지침 E에 따라 이전 S-8 등록(파일 번호 333-265984, 333-274125, 333-281610)을 포함하여 이루어졌습니다.

회사는 비가속 신고자(non-accelerated filer)소형 보고 회사(smaller reporting company)로 분류됩니다. 재무 결과, 수익 전망 또는 거래 공개는 포함되어 있지 않으며, 문서는 주식 보상 증권 등록만을 위한 것입니다. Sheppard, Mullin, Richter & Hampton LLP가 법률 의견서(증거 5.1)를 제공했으며 WithumSmith+Brown, PC가 감사인 동의서(증거 23.1)를 제출했습니다.

효력이 발생하면 새로 등록된 주식은 옵션, RSU 또는 전시 색인에 나열된 기타 상여 계약을 통해 발행될 수 있습니다. 서명 페이지에는 CEO Robb Knie와 CFO David Briones가 포함되어 있으며, 향후 수정에 대한 포괄 위임장이 포함되어 있습니다.

Hoth Therapeutics, Inc. (NASDAQ : HOTH) a déposé un formulaire S-8 pour enregistrer 2 000 000 d'actions ordinaires supplémentaires à émettre dans le cadre de son Plan d'Incitation Globale aux Actions 2022 modifié et révisé. Suite à l'approbation des actionnaires le 5 août 2025, le total disponible dans le plan est passé à 3 091 317 actions, contre 1 091 317 auparavant. Le dépôt est effectué conformément à l'Instruction Générale E, incorporant les enregistrements S-8 antérieurs (numéros de dossier 333-265984, 333-274125, 333-281610).

La société est classée comme non-accelerated filer et smaller reporting company. Aucun résultat financier, prévision de bénéfices ou divulgation transactionnelle n'est inclus ; le document se limite à l'enregistrement de titres de rémunération en actions. Sheppard, Mullin, Richter & Hampton LLP a fourni l'avis juridique (Exhibit 5.1) et WithumSmith+Brown, PC a donné son consentement en tant qu'auditeur (Exhibit 23.1).

Une fois effectif, les actions nouvellement enregistrées pourront être émises via des options, des RSU ou d'autres accords de récompense listés dans l'index des pièces. Les pages de signature comprennent le PDG Robb Knie et le directeur financier David Briones, avec une procuration générale pour les modifications futures.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) hat ein Formular S-8 eingereicht, um zusätzlich 2.000.000 Stammaktien zur Ausgabe im Rahmen seines geänderten und neu gefassten Omnibus-Aktienanreizplans 2022 zu registrieren. Nach der Zustimmung der Aktionäre am 5. August 2025 erhöhte sich der Gesamtpool unter dem Plan auf 3.091.317 Aktien, zuvor 1.091.317. Die Einreichung erfolgt gemäß Allgemeiner Anweisung E und beinhaltet frühere S-8-Registrierungen (Aktenzeichen 333-265984, 333-274125, 333-281610).

Das Unternehmen ist als non-accelerated filer und smaller reporting company klassifiziert. Es sind keine Finanzergebnisse, Gewinnprognosen oder transaktionsbezogenen Offenlegungen enthalten; das Dokument dient ausschließlich der Registrierung von Aktienvergütungswertpapieren. Sheppard, Mullin, Richter & Hampton LLP erteilte die Rechtsmeinung (Anlage 5.1) und WithumSmith+Brown, PC stimmte als Prüfer zu (Anlage 23.1).

Nach Wirksamwerden können die neu registrierten Aktien durch Optionen, RSUs oder andere im Ausstellungsverzeichnis aufgeführte Prämienvereinbarungen ausgegeben werden. Die Unterschriftsseiten enthalten CEO Robb Knie und CFO David Briones, mit einer umfassenden Vollmacht für künftige Änderungen.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

Why did HOTH file a new Form S-8 on 5-Aug-2025?

To register 2,000,000 additional shares for issuance under its Amended & Restated 2022 Omnibus Equity Incentive Plan.

How many total shares are now reserved under HOTH's 2022 Equity Plan?

The share reserve increased to 3,091,317 following shareholder approval.

Does the filing immediately increase HOTH's shares outstanding?

No. Shares are only issued when equity awards are granted and subsequently exercised or vest.

What filer status does HOTH report in this S-8?

HOTH identifies as a non-accelerated filer and a smaller reporting company.

Which law firm provided the opinion for this registration?

Sheppard, Mullin, Richter & Hampton LLP issued the legal opinion (Exhibit 5.1).

Were prior S-8 registrations incorporated?

Yes, prior filings 333-265984, 333-274125, 333-281610 are incorporated by reference.
Palantir Technologies Inc

NASDAQ:PLTR

PLTR Rankings

PLTR Latest News

PLTR Latest SEC Filings

PLTR Stock Data

411.06B
2.18B
3.64%
55.88%
2.28%
Software - Infrastructure
Services-prepackaged Software
Link
United States
DENVER